Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells

Cancer Research

Volumn 57, Issue 24, 1997, Pages 5584-5589

  Cao, Yu An ^a   Gao, Qingshen ^a   Wazer, David E ^a   Band, Vimla ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TELOMERASE;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CARCINOGENESIS; CELL IMMORTALIZATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MUTATION; PRIORITY JOURNAL;

BREAST; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; ENZYME INDUCTION; EPITHELIAL CELLS; FEMALE; HUMANS; MUTATION; TELOMERASE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031468362     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Wazer, D. E., Liu, X-L., Chu, Q., Gao, Q., and Band, V. Immortalisation of distinct human mammary epithelial cell types by human papilloma virus-16 E6 or E7. Proc. Natl. Acad. Sci. USA, 92: 3687-3691, 1995.
2. Gao, Q., Hauser, S. H., Liu, X-L., Wazer, D. E., Madoc-Jones, H., and Band, V. Mutant p53-induced immortalization of primary human mammary epithelial cells. Cancer Res., 56; 3129-3133, 1996.
3. Bartek, J., Bartkova, J., Kyprianou, N., Lalani, E. N., Staskova, Z., Shearer, M., Chang, S., and Taylor-Papadimitriou, J. Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with recombinant retrovirus. Proc. Natl. Acad. Sci. USA. 88: 3520-3524, 1991.
4. Stampfer, M. R., and Bartley, J. C. Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo(a)pyrene. Proc. Natl. Acad. Sci. USA, 82: 2394-2398, 1985.
5. Clark, R., Stampfer, M. R., Milley, R., O'Rourke, E., Walen, K. H., Kriegler, M., Kopplin, J., and McCormick, F. Transformation of human mammary epithelial cells by oncogenic retroviruses. Cancer Res., 48: 4689-4694, 1988.
6. Pierce, J. H., Arnstein, P., DiMarco, E., Artrip, J., Kraus, M. H., Lonardo, F., Di Fiore, P. P., and Aaronson, S. A. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene, 6: 1189-1194, 1991.
7. Zhai, Y. F., Beittenmiller, H., Wang, B., Gould, M. N., Oakley, C., Esselman, W. J., and Welsch, C. W. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res., 53: 2272-2278, 1993.
8. Soule, H. D., Maloney, T. M., Wolman, S. R., Peterson, W. D., Brenz, R., McGrath, C. M., Russo, J., Pauley, R. J., Jones, R. F., and Brooks, S. C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res., 50: 6075-6086, 1990.
9. Briand, P., Petersen, O. W., and Van Deurs, B. A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cell. Dev. Biol., 23: 181-188, 1987.
10. Shay, J. W., Tomlinson, G., Piatyszek, M. A., and Gollahon, L. S. Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol. Cell. Biol., 15: 425-432, 1995.
11. Hammond, S. L., Ham, R. G., and Stampfer, M. R. Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc. Natl. Acad. Sci. USA, 81: 5435-5439, 1984.
12. Band, V., and Sager, R. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc. Natl. Acad. Sci. USA, 86: 1249-1253, 1989.
13. Kennedy, M. J., and Abeloff, M. D. Management of locally recurrent breast cancer. Cancer (Phila.), 71: 2395-2409, 1993.
14. Fisher, E. R., Anderson, S., Redmond, C., and Fisher, B. Ipsilaterial breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Semin. Surg. Oncol., 8: 161-166, 1992.
15. Barrett, J. C. Comparison of human versus rodent cell transformation: importance of cell aging. In: J. S. Rhim and A. Dritschilo (eds.). Neoplastic Transformation in Human Cell Culture, pp. 3-13. New York: Humana Press, 1991.
16. Zur Hausen, H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr. Top. Microbiol. Immunol., 186: 131-156, 1994.
17. Band, V., DeCaprio, J. A., Delmolino, L., Kulesa, V., and Sager, R. Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J. Virol., 65: 6671-6676, 1991.
18. Band, V., Dalal, S., Delmolino, L., and Androphy, E. J. Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J., 12: 1847-1852, 1993.
19. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
20. Crook, T., Tidy, J. A., and Vousden, K. H. Degradation of p53 can be targeted by HPV-E6 sequences distinct from those required for p53 binding and transactivation. Cell, 67: 547-556, 1991.
21. Dalal, S., Gao, Q., Androphy, E. J., and Band, V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol., 70: 683-688, 1996.
22. Wazer, D. E., Chu, Q., Liu, X-L., Gao, Q., Safaii, H., and Band, V. Loss of p53 protein during radiation transformation of primary human mammary epithelial cells. Mol. Cell. Biol., 14: 2468-2478, 1994.
23. Jego, N., Thomas, G., and Hamelin, R. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene, 8: 209-213, 1993.
24. Runnebaum, I. B., Nagarajan, M., Bowman, M., Soto, D., and Sukumar, S. Mutations in p53 as potential molecular markers for human breast cancer. Proc. Natl. Acad. Sci. USA, 88: 10657-10661, 1991.
25. Gollahon, L. S., and Shay, J. W. Immortalization of human mammary epithelial cells transfected with mutant p53 (273His). Oncogene, 12: 715-725, 1996.
26. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
27. Chen, J-Y., Funk, W. D., Wright, W. E., Shay, J. W., and Minna, J. D. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene, 8: 2159-2166, 1993.
28. Kern, S. E. p53: tumor suppression through control of the cell cycle. Gastroenterology, 106: 1708-1711, 1994.
29. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell, 71: 587-597, 1992.
30. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 Oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
31. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
32. Okamoto, K., and Beach, D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J., 13: 4816-4822, 1994.
33. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80: 293-299, 1995.
34. Buckbinder, L., Talbort, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., and Kley, N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature (Lond.), 377: 646-649, 1995.
35. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
36. Ko, L. J., and Prives, C. p53: puzzle and paradigm. Genes Dev., 10: 1054-1072, 1996.
37. Milner, J., and Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell, 65: 765-774, 1991.
38. Shay, J. W., and Wright, E. W. E. Telomerase activity in human cancer. Curr. Opin. Cancer, 8: 66-71, 1996.
39. Klingelnutz, A. J., Foster, S. A., and McDougall, J. K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature (Lond.), 380: 79-82, 1996.
40. Piatyszek, M. A., Kim, N. W., Weinrich, S. L., Hiyama, K., Hiyama, E., Wright, W. E., and Shay, J. W. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci., 17: 1-15, 1995.
41. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
42. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
43. Paulovich, A. G., Toczyski, D. P., and Hartwell, L. H. When checkpoints fail. Cell, 88: 315-321, 1997.
44. Prives, C. How loops, β sheets, and α helices help us to understand p53. Cell, 78: 543-546, 1994.
45. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Washington DC), 265: 346-356, 1994.
46. Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Band, V., Wang, X. W., and Harris, C. C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10: 2103-2111, 1995.
47. Crook, T., Marston, N. J., Sara, E. A., and Vousden, K. H. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell, 79: 817-828, 1994.
48. Murphy, M., Hinman, A., and Levine, A. J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev., 10: 2971-2980, 1996.
49. Mack, D. H., Vartikar, J., Pipas, J. M., and Laimonis, L. A. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature (Lond.), 363: 281-283, 1993.
50. Sabbatini, P., Chiou, S-K., Rao, L., and White, E. Modulation of p53-Mediated transcriptional repression and apoptosis by adenovirus E1B 19K protein. Mol. Cell. Biol., 15: 1060-1070, 1995.
51. Mercer, W. E., Shields, M. T., Lin, D., Appella, E., and Ullrich, S. J. Growth suppression induced by wild-type p53 protein is accompanied by selective downregulation of proliferating-cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA, 88: 1958-1962, 1991.
52. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-46, 1993.
53. Lin, J., Teresky, A. K., and Levine, A. J. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene, 10: 2387-2390, 1995.